Development and Longevity of Naturally Acquired Antibody and Memory B Cell Responses Against Plasmodium Vivax Infection

Overview

Journal PLoS Negl Trop Dis

Specialties Infectious Diseases
Tropical Medicine

Date 2024 Oct 24

PMID 39446698

Authors

Pongsakorn Thawornpan

Piyawan Kochayoo

Zulfa Zahra Salsabila

Patchanee Chootong

Affiliations

Soon will be listed here.

Abstract

Plasmodium vivax malaria causes significant public health problems in endemic regions. Considering the rapid spread of drug-resistant parasite strains and the development of hypnozoites in the liver with potential for relapse, development of a safe and effective vaccine for preventing, controlling, and eliminating the infection is critical. Immunity to malaria is mediated by antibodies that inhibit sporozoite or merozoite invasion into host cells and protect against clinical disease. Epidemiologic data from malaria endemic regions show the presence of naturally acquired antibodies to P. vivax antigens during and following infection. But data on the persistence of these antibodies, development of P. vivax-specific memory B cells (MBCs), and their relation to reduction of malaria severity and risk is limited. This review provides an overview of the acquisition and persistence of naturally acquired humoral immunity to P. vivax infection. Also, we summarize and discuss current progress in assessment of immune responses to candidate vaccine antigens in P. vivax patients from different transmission settings. Longitudinal studies of MBC and antibody responses to these antigens will open new avenues for developing vaccines against malaria infection and its transmission.

Citing Articles

Atypical memory B cells from natural malaria infection produced broadly neutralizing antibodies against Plasmodium vivax variants.

Kochayoo P, Moriyama S, Kotaki R, Thawornpan P, Malee C, Leepiyasakulchai C PLoS Pathog. 2025; 21(1):e1012866.

PMID: 39847574 PMC: 11756785. DOI: 10.1371/journal.ppat.1012866.

References

Ceravolo I, Sanchez B, Sousa T, Guerra B, Soares I, Braga E . Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol. 2009; 156(3):502-10. PMC: 2691980. DOI: 10.1111/j.1365-2249.2009.03931.x. View

Obeng-Adjei N, Portugal S, Holla P, Li S, Sohn H, Ambegaonkar A . Malaria-induced interferon-γ drives the expansion of Tbethi atypical memory B cells. PLoS Pathog. 2017; 13(9):e1006576. PMC: 5633206. DOI: 10.1371/journal.ppat.1006576. View

Wu Y, Ellis R, Shaffer D, Fontes E, Malkin E, Mahanty S . Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One. 2008; 3(7):e2636. PMC: 2440546. DOI: 10.1371/journal.pone.0002636. View

Kar S, Sinha A . Duffy Binding Protein-Based Vaccine: a Distant Dream. Front Cell Infect Microbiol. 2022; 12:916702. PMC: 9325973. DOI: 10.3389/fcimb.2022.916702. View

Patgaonkar M, Herbert F, Powale K, Gandhe P, Gogtay N, Thatte U . Vivax infection alters peripheral B-cell profile and induces persistent serum IgM. Parasite Immunol. 2018; 40(10):e12580. DOI: 10.1111/pim.12580. View

Thawornpan P, Nicholas J, Malee C, Kochayoo P, Wangriatisak K, Tianpothong P . Longitudinal analysis of antibody responses to Plasmodium vivax sporozoite antigens following natural infection. PLoS Negl Trop Dis. 2024; 18(1):e0011907. PMC: 10817200. DOI: 10.1371/journal.pntd.0011907. View

Ambegaonkar A, Holla P, Dizon B, Sohn H, Pierce S . Atypical B cells in chronic infectious diseases and systemic autoimmunity: puzzles with many missing pieces. Curr Opin Immunol. 2022; 77:102227. PMC: 9612402. DOI: 10.1016/j.coi.2022.102227. View

Park J, Moon S, Yeom J, Lim K, Sohn M, Jung W . Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea. Clin Diagn Lab Immunol. 2001; 8(1):14-20. PMC: 96005. DOI: 10.1128/CDLI.8.1.14-20.2001. View

Weiss G, Traore B, Kayentao K, Ongoiba A, Doumbo S, Doumtabe D . The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog. 2010; 6(5):e1000912. PMC: 2873912. DOI: 10.1371/journal.ppat.1000912. View

10.

Phyo A, Dahal P, Mayxay M, Ashley E . Clinical impact of vivax malaria: A collection review. PLoS Med. 2022; 19(1):e1003890. PMC: 8765657. DOI: 10.1371/journal.pmed.1003890. View

11.

Kuamsab N, Putaporntip C, Kakino A, Kosuwin R, Songsaigath S, Tachibana H . Anti-Plasmodium vivax merozoite surface protein 3 ϒ (PvMSP3 ϒ) antibodies upon natural infection. Sci Rep. 2024; 14(1):9595. PMC: 11053162. DOI: 10.1038/s41598-024-59153-w. View

12.

Chen J, Chen S, Wang Y, Ju C, Zhang T, Xu B . An immunomics approach for the analysis of natural antibody responses to Plasmodium vivax infection. Mol Biosyst. 2015; 11(8):2354-63. DOI: 10.1039/c5mb00330j. View

13.

Wongkidakarn S, McHenry A, Sattabongkot J, Adams J, Chootong P . Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II. PLoS One. 2016; 11(5):e0154577. PMC: 4856259. DOI: 10.1371/journal.pone.0154577. View

14.

Gentil F, Bargieri D, Leite J, Francoso K, Patricio M, Espindola N . A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. Vaccine. 2010; 28(38):6183-90. DOI: 10.1016/j.vaccine.2010.07.017. View

15.

Weiss G, Crompton P, Li S, Walsh L, Moir S, Traore B . Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol. 2009; 183(3):2176-82. PMC: 2713793. DOI: 10.4049/jimmunol.0901297. View

16.

Nguemwo Tentokam B, Amaratunga C, Alani N, Macdonald N, Narum D, Salinas N . Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1. Front Immunol. 2019; 10:2295. PMC: 6788386. DOI: 10.3389/fimmu.2019.02295. View

17.

Dewasurendra R, Jeffreys A, Gunawardena S, Chandrasekharan N, Rockett K, Kwiatkowski D . Host genetic polymorphisms and serological response against malaria in a selected population in Sri Lanka. Malar J. 2018; 17(1):473. PMC: 6296029. DOI: 10.1186/s12936-018-2622-9. View

18.

Tashi T, Upadhye A, Kundu P, Wu C, Menant S, Soares R . Longitudinal IgG antibody responses to Plasmodium vivax blood-stage antigens during and after acute vivax malaria in individuals living in the Brazilian Amazon. PLoS Negl Trop Dis. 2022; 16(11):e0010773. PMC: 9728838. DOI: 10.1371/journal.pntd.0010773. View

19.

Julien J, Wardemann H . Antibodies against Plasmodium falciparum malaria at the molecular level. Nat Rev Immunol. 2019; 19(12):761-775. DOI: 10.1038/s41577-019-0209-5. View

20.

Malkin E, Durbin A, Diemert D, Sattabongkot J, Wu Y, Miura K . Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005; 23(24):3131-8. PMC: 10994215. DOI: 10.1016/j.vaccine.2004.12.019. View